Evaluation of the impact of GLP-1 receptor agonists (RAs) on stage of PDAC diagnosis: A retrospective matched cohort study.

Le résumé fourni par la source

e16462 Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is most frequently diagnosed at either the locally advanced or metastatic setting. Most patients will not have the opportunity for curative-intent surgical resection. The early symptoms of pancreatic cancer, including weight loss, early satiety, and back and/or abdominal pain, provide clinical clues that can trigger a medical evaluation and diagnosis of PDAC. GLP-1 (glucagon-like peptide-1) receptor agonists (RAs) are widely used for type 2 diabetes and obesity management. However, the side effects of GLP-1 RAs include early satiety, diarrhea, and weight loss. This potential overlap in drug effects and cancer symptoms raises the question of delayed PDAC diagnosis in patients on GLP-1 RAs. We conducted a retrospective matched cohort study of patients diagnosed with PDAC to evaluate whether GLP1 RAs were associated with a later stage of diagnosis. Methods: Eighty-eight patients with PDAC on a GLP-1 RA at the time of diagnosis were matched 2:1 by age, ECOG status, and diagnosis date to 176 patients with PDAC who were not on a GLP-1 RA at the time of diagnosis. Extensive clinical information was gathered, including stage at diagnosis [resectable, borderline resectable (BRPC), locally advanced (LAPC), or metastatic (mPDAC)], diagnosis of diabetes, treatments, and outcomes. Risks of diagnosis at each stage were estimated using multinomial logistic regression. Results: GLP-1 RA users had 21.7 percentage point higher risk of diagnosis with BRPC than resectable PDAC, as compared to non-GLP-1 RA users (p = .035), and were 12.0 and 12.5 percentage points more likely to be diagnosed as LAPC or mPDAC than resectable disease, respectively. After weighting adjustment for diabetes mellitus diagnosis, GLP-1 RA users were 18.6 percentage points more likely to be diagnosed with BRPC vs. resectable disease (p = 0.09). 39% of non-GLP-1 RA users underwent curative-intent surgical resection compared to 27% of users (p = 0.065). Conclusions: In this small retrospective matched cohort study, we observed that patients who were taking GLP-1 RA agonists at the time of PDAC diagnosis were more likely to be diagnosed with non-resectable disease compared to a matched group of patients who were not taking GLP-1 RAs. This observation may be due to an overlap in symptoms between GLP-1 RA and PDAC, leading clinicians to attribute satiety and weight loss to the agent. Clinicians should be attentive to the symptoms of patients on GLP-1 RAs, particularly if symptoms are out of proportion to what is expected with the use of this drug class. Stage Difference in risk differences (GLP-1 minus non-GLP-1) Std. Err. p-value BRPC vs. resectable 0.217 0.080 0.035 LAPC vs. resectable 0.120 0.087 0.217 mPDAC vs. resectable 0.125 0.101 0.263

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.